SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023



First results will be presented from early-stage clinical trials of BL-M07D1, antibody-drug conjugate (ADC) targeting HER2 with the payload Ed-04 Clinical progress will be presented from early-stage clinical trials of BL-B01D1, the bi-specific antibody-drug conjugate (ADC) targeting EGFR…

Leave a Reply